Moore Capital Management’s PTC Therapeutics PTCT Stock Holding History

Moore Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.17M	Buy	75,588 +30,894	+69%	+$2.23M	0.09%	193
2026 Q1	$3.05M	Buy	+44,694	New	+$3.16M	0.06%	223
2023 Q3	–	Sell	-25,000	Closed	-$930K	–	575
2023 Q2	$1.02M	Sell	25,000 -3,500	-12%	-$171K	0.02%	309
2023 Q1	$1.38M	Sell	28,500 -1,500	-5%	-$68.6K	0.03%	271
2022 Q4	$1.15M	Buy	30,000 +10,000	+50%	+$416K	0.03%	318
2022 Q3	$1M	Sell	20,000 -20,000	-50%	-$980K	0.02%	407
2022 Q2	$1.6M	Hold	40,000	–	–	0.04%	361
2022 Q1	$1.49M	Hold	40,000	–	–	0.04%	400
2021 Q4	$1.59M	Hold	40,000	–	–	0.03%	422
2021 Q3	$1.49M	Hold	40,000	–	–	0.02%	479
2021 Q2	$1.69M	Hold	40,000	–	–	0.02%	489
2021 Q1	$1.89M	Sell	40,000 -1,572	-4%	-$93.4K	0.02%	463
2020 Q4	$2.54M	Sell	41,572 -8,428	-17%	-$497K	0.03%	330
2020 Q3	$2.34M	Buy	50,000 +10,000	+25%	+$492K	0.04%	252
2020 Q2	$2.03M	Hold	40,000	–	–	0.05%	190
2020 Q1	$1.78M	Sell	40,000 -170,611	-81%	-$8.59M	0.07%	117
2019 Q4	$10.1M	Sell	210,611 -27,844	-12%	-$1.18M	0.33%	86
2019 Q3	$8.06M	Buy	238,455 +48,337	+25%	+$2.1M	0.32%	93
2019 Q2	$8.55M	Buy	190,118 +90,118	+90%	+$3.56M	0.2%	114
2019 Q1	$3.76M	Buy	100,000 +10,000	+11%	+$336K	0.12%	173
2018 Q4	$3.09M	Sell	90,000 -10,000	-10%	-$360K	0.12%	123
2018 Q3	$4.7M	Hold	100,000	–	–	0.1%	142
2018 Q2	$3.37M	Sell	100,000 -75,000	-43%	-$2.34M	0.08%	158
2018 Q1	$4.74M	Buy	175,000 +125,000	+250%	+$3.17M	0.09%	145
2017 Q4	$834K	Hold	50,000	–	–	0.02%	217
2017 Q3	$1M	Sell	50,000 -50,000	-50%	-$979K	0.02%	191
2017 Q2	$1.83M	Hold	100,000	–	–	0.06%	140
2017 Q1	$984K	Buy	100,000 +50,000	+100%	+$605K	0.03%	167
2016 Q4	$546K	Sell	50,000 -50,000	-50%	-$525K	0.02%	155
2016 Q3	$1.4M	Buy	+100,000	New	+$813K	0.05%	145
2015 Q3	–	Sell	-43,000	Closed	-$2.07M	–	379
2015 Q2	$2.07M	Buy	43,000 +23,000	+115%	+$1.34M	0.04%	310
2015 Q1	$1.22M	Buy	+20,000	New	+$1.22M	0.03%	337

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Moore Capital Management's PTCT Position: Q2 2026 in Review

Moore Capital Management increased its PTC Therapeutics (PTCT) stake by 69% in Q2 2026, buying an estimated $2.23M and bringing the position to 75,588 shares worth $6.17M. The position accounts for 0.09% of the portfolio, ranked #193.

Moore Capital Management first reported a position in PTCT in Q1 2015 and has held it in 32 quarters since. The position peaked at $10.1M in Q4 2019. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Moore Capital Management held 75,588 shares of PTC Therapeutics worth $6.17M as of Q2 2026.
Moore Capital Management bought 30,894 PTC Therapeutics shares in Q2 2026, an estimated $2.23M.
PTC Therapeutics made up 0.09% of Moore Capital Management's portfolio in Q2 2026, its #193 holding.
Moore Capital Management first reported a position in PTC Therapeutics in Q1 2015 and has held it in 32 quarters since.
Moore Capital Management's PTC Therapeutics position peaked at $10.1M in Q4 2019.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.